BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
8.80
+0.01 (0.11%)
At close: Apr 28, 2026, 4:00 PM EDT
8.97
+0.17 (1.93%)
After-hours: Apr 28, 2026, 6:08 PM EDT
BBOT Employees
BridgeBio Oncology Therapeutics had 92 employees as of December 31, 2025. The number of employees increased by 30 or 48.39% compared to the previous year.
Employees
92
Change (1Y)
30
Growth (1Y)
48.39%
Revenue / Employee
n/a
Profits / Employee
-$1,457,000
Market Cap
704.29M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 92 | 30 | 48.39% |
| Dec 31, 2024 | 62 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Arvinas | 246 |
| Allogene Therapeutics | 152 |
| Absci | 140 |
| Solid Biosciences | 121 |
| Alpha Tau Medical | 121 |
| Lexicon Pharmaceuticals | 81 |
| Relmada Therapeutics | 17 |
BBOT News
- 6 days ago - BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 - GlobeNewsWire
- 6 days ago - BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman - GlobeNewsWire
- 7 days ago - BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 - GlobeNewsWire
- 8 days ago - BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 5 weeks ago - BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 7 weeks ago - BridgeBio Oncology Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor - GlobeNewsWire
- 7 weeks ago - BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress - GlobeNewsWire